The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...

Significant improvements in skin toxicity were observed by week 6 in all patients treated with HT-001 in the phase 2a ...

The addition of lenvatinib/pembrolizumab to TACE showed a numerical improvement in PFS, but longer follow-up is necessary to ...

Improved education on drug toxicity management, especially within the first 90 days of treatment and regarding individualized ...

Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have ...

Findings from an exploratory 2a study showed improvements in patients with cancer cachexia with PH284 compared with placebo.